Clinical Trials Browser

Phase 1/2 × Pancreatic Adenocarcinoma × durvalumab × Clear all

NCT03245541 2025-10-07

Radiation Therapy in Combination With Durvalumab for People With Pancreatic Cancer

Phase 1/2 Active not recruiting

Gastrointestinal

Pancreatic Adenocarcinoma